SecBot SecBot

MADE in America Act

H.R. 2707 Rep. Earl Carter (R-GA-1) In committee
Bill text PDF
  1. Introduced Apr 19
  2. Committee Apr 19
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Apr 19, 2023Next: House vote
680d ago Dec 17, 2024: Referred to the Subcommittee on Health.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Biotech & Pharma 1
Search all 1 companies, their asks and price moves Subscribe

Summary

Manufacturing API, Drugs, and Excipients in America Act or the MADE in America Act

Full summary3 paragraphs

This bill establishes a tax credit for certain manufacturers of pharmaceuticals or medical products.

Specifically, the bill establishes a tax credit for manufacturers of pharmaceuticals, active pharmaceutical ingredients, excipients (i.e., inactive ingredients), medical diagnostic devices, or personal protective equipment, if they are located in a designated distressed zone. The tax credit is equal to 25% of the manufacturer's production expenditures; the credit increases to 30% of expenditures if a substantial portion of the manufacturer's employees reside in a distressed zone.

The bill defines distressed zone as an area that has been designated as a qualified opportunity zone by the Internal Revenue Service (i.e., an economically distressed community in which certain new investments may be eligible for preferential tax treatment) and that has a poverty rate of over 30%.

Library of Congress summary, Apr 19, 2023

Summary versions
  • Introduced in HouseApr 19, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.